This Robotics Giant Just Became A BUY: Intuitive Surgical Real Betis - Elche C. F. [sYrpyss0m9Z]

Get the FREE report 7 Best Space Stocks To Own in 2026:

Intuitive Surgical ran hard into November last year then pulled back sharply. For long-term investors, that pullback may be the more interesting story.

We break down why the decline doesn't reflect what's actually happening inside the business. The April earnings report showed 17% growth in surgical procedures and 235 new system placements in a single quarter. The razor-and-blade model means every one of those placements generates recurring consumables revenue that compounds over time. On top of that, the company secured FDA clearance for force feedback technology, launched the Da Vinci 5 system with a dramatic leap in computational power, and most significantly Japan's government authorized reimbursement for seven robotic surgery types effective June 2026.

There's also a July 28th earnings report on the horizon that investors should be watching closely.

For investors building exposure to physical AI and medical robotics, the case for why now could be a valid entry point is worth understanding in full.

Watch the full interview on @MarketBeatMedia

MarketBeat provides stock research, market analysis, and investing tools for self-directed investors.

MarketBeat Clips delivers quick, stock-specific insights from the best conversations on the MarketBeat Media channel.

Subscribe for stock analysis, investing ideas, market commentary, and short-form clips covering the stocks and sectors investors are watching most.

Text YouTube to 68285 for free stock alerts and local elections 2026 results time market updates.

DISCLAIMER: MarketBeats videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not michael jackson thriller registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves riskincluding the potential loss of principalso always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is john cooper clarke not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.